IPHA Valuation

Innate Pharma SA

Add to Watchlist

Advanced Chart

2.020

-0.06(-2.885%)1D

Overview
Forecast
Valuation
Earnings

IPHA Relative Valuation

IPHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IPHA is overvalued; if below, it's undervalued.

Historical Valuation

Innate Pharma SA (IPHA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.35 is considered Undervalued compared with the five-year average of -2.68. The fair price of Innate Pharma SA (IPHA) is between 2.21 to 4.33 according to relative valuation methord. Compared to the current price of 2.08 USD , Innate Pharma SA is Undervalued By 6.09%.

Relative Value

Fair Zone

2.21-4.33

Current Price：2.08

6.09%

Undervalued

-3.47

Trailing

Forward

-7.53

EV/EBITDA

Innate Pharma SA. (IPHA) has a current EV/EBITDA of -7.53. The 5-year average EV/EBITDA is -5.70. The thresholds are as follows: Strongly Undervalued below -11.70, Undervalued between -11.70 and -8.70, Fairly Valued between -2.69 and -8.70, Overvalued between -2.69 and 0.31, and Strongly Overvalued above 0.31. The current Forward EV/EBITDA of -7.53 falls within the Historic Trend Line -Fairly Valued range.

-33.78

EV/EBIT

Innate Pharma SA. (IPHA) has a current EV/EBIT of -33.78. The 5-year average EV/EBIT is -7.82. The thresholds are as follows: Strongly Undervalued below -28.96, Undervalued between -28.96 and -18.39, Fairly Valued between 2.76 and -18.39, Overvalued between 2.76 and 13.33, and Strongly Overvalued above 13.33. The current Forward EV/EBIT of -33.78 falls within the Strongly Undervalued range.

2.35

Innate Pharma SA. (IPHA) has a current PS of 2.35. The 5-year average PS is 4.10. The thresholds are as follows: Strongly Undervalued below 1.12, Undervalued between 1.12 and 2.61, Fairly Valued between 5.59 and 2.61, Overvalued between 5.59 and 7.08, and Strongly Overvalued above 7.08. The current Forward PS of 2.35 falls within the Undervalued range.

3.74

P/OCF

Innate Pharma SA. (IPHA) has a current P/OCF of 3.74. The 5-year average P/OCF is -74.84. The thresholds are as follows: Strongly Undervalued below -622.93, Undervalued between -622.93 and -348.89, Fairly Valued between 199.21 and -348.89, Overvalued between 199.21 and 473.25, and Strongly Overvalued above 473.25. The current Forward P/OCF of 3.74 falls within the Historic Trend Line -Fairly Valued range.

4.16

P/FCF

Innate Pharma SA. (IPHA) has a current P/FCF of 4.16. The 5-year average P/FCF is -5.54. The thresholds are as follows: Strongly Undervalued below -71.35, Undervalued between -71.35 and -38.45, Fairly Valued between 27.37 and -38.45, Overvalued between 27.37 and 60.28, and Strongly Overvalued above 60.28. The current Forward P/FCF of 4.16 falls within the Historic Trend Line -Fairly Valued range.

Innate Pharma SA (IPHA) has a current Price-to-Book (P/B) ratio of 16.85. Compared to its 3-year average P/B ratio of 6.23 , the current P/B ratio is approximately 170.29% higher. Relative to its 5-year average P/B ratio of 4.56, the current P/B ratio is about 269.75% higher. Innate Pharma SA (IPHA) has a Forward Free Cash Flow (FCF) yield of approximately -4.29%. Compared to its 3-year average FCF yield of -11.96%, the current FCF yield is approximately -64.16% lower. Relative to its 5-year average FCF yield of -13.83% , the current FCF yield is about -69.00% lower.

16.85

P/B

Median3y

6.23

Median5y

4.56

-4.29

FCF Yield

Median3y

-11.96

Median5y

-13.83

Competitors Valuation Multiple

The average P/S ratio for IPHA's competitors is 1.78, providing a benchmark for relative valuation. Innate Pharma SA Corp (IPHA) exhibits a P/S ratio of 2.35, which is 31.78% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

China SXT Pharmaceuticals Inc

Performance Decomposition

Market capitalization of IPHA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IPHA in the past 1 year is driven by Unknown.